International Journal of Radiation Oncology * Biology * Physics
Volume 75, Issue 1 , Pages 203-211 , 1 September 2009

The Prognostic Value of TRAIL and its Death Receptors in Cervical Cancer

  • John H. Maduro, M.D.

      Affiliations

    • Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • Corresponding Author InformationReprint requests to: J. H. Maduro, M.D., Department of Radiation Oncology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands. Tel: (+31) 50-3619382; Fax: (+31) 50-3611692
    • ,
  • Maartje G. Noordhuis, B.Sc.

      Affiliations

    • Department of Gynecologic Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • ,
  • Klaske A. ten Hoor

      Affiliations

    • Department of Gynecologic Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • ,
  • Elisabeth Pras, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • ,
  • Henriette J.G. Arts, M.D., Ph.D.

      Affiliations

    • Department of Gynecologic Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • ,
  • Jasper J.H. Eijsink, M.D.

      Affiliations

    • Department of Gynecologic Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • ,
  • Harry Hollema, M.D., Ph.D.

      Affiliations

    • Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • ,
  • Constantijne H. Mom, M.D., Ph.D.

      Affiliations

    • Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • Department of Gynecologic Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • ,
  • Steven de Jong, Ph.D.

      Affiliations

    • Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • ,
  • Elisabeth G.E. de Vries, M.D., Ph.D.

      Affiliations

    • Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • ,
  • Geertruida H. de Bock, Ph.D.

      Affiliations

    • Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    • ,
  • Ate G.J. van der Zee, M.D., Ph.D.

      Affiliations

    • Department of Gynecologic Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Received 7 November 2008 ,Revised 1 March 2009 ,Accepted 13 March 2009.

References 

  1. Lehman M, Thomas G. Is concurrent chemotherapy and radiotherapy the new standard of care for locally advanced cervical cancer?. Int J Gynecol Cancer. 2001;11:87–99
  2. Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. Lancet. 2001;358:781–786
  3. Maduro JH, Pras E, Willemse PH, et al. Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev. 2003;29:471–488
  4. Hougardy BM, Maduro JH, van der Zee AG, et al. Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: Changing the apoptotic balance. Lancet Oncol. 2005;6:589–598
  5. Duiker EW, Mom CH, de Jong S, et al. The clinical trail of TRAIL. Eur J Cancer. 2006;42:2233–2240
  6. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002;2:420–430
  7. Maduro JH, de Vries EG, Meersma GJ, et al. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis. Int J Radiat Oncol Biol Phys. 2008;72:543–552
  8. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 2008;26:3621–3630
  9. Tolcher AW, Mita M, Meropol NJ, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol. 2007;25:1390–1395
  10. Reesink-Peters N, Hougardy BM, van den Heuvel FA, et al. Death receptors and ligands in cervical carcinogenesis: An immunohistochemical study. Gynecol Oncol. 2005;96:705–713
  11. Zhang XD, Nguyen T, Thomas WD, et al. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett. 2000;482:193–199
  12. Hougardy BM, Reesink-Peters N, van den Heuvel FA, et al. A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants. Int J Cancer. 2008;123:1457–1465
  13. Koornstra JJ, Kleibeuker JH, van Geelen CM, et al. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol. 2003;200:327–335
  14. Ryu HS, Chang KH, Chang SJ, et al. Expression of TRAIL (TNF-related apoptosis-inducing ligand) receptors in cervical cancer. Int J Gynecol Cancer. 2000;10:417–424
  15. Arts HJ, de Jong S, Hollema H, et al. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma. Gynecol Oncol. 2004;92:794–800
  16. Spierings DC, de Vries EG, Timens W, et al. Expression of TRAIL and TRAIL death receptors in Stage III non–small cell lung cancer tumors. Clin Cancer Res. 2003;9:3397–3405
  17. van Geelen CM, Westra JL, de Vries EG, et al. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated Stage III colon cancer patients. J Clin Oncol. 2006;24:4998–5004
  18. McCarthy MM, Sznol M, DiVito KA, et al. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res. 2005;11:5188–5194
  19. Lancaster JM, Sayer R, Blanchette C, et al. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. Clin Cancer Res. 2003;9:762–766
  20. Zhuang L, Lee CS, Scolyer RA, et al. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. Hum Pathol. 2006;37:1286–1294
  21. Trott KR. Can tumour response be assessed from a biopsy?. Br J Cancer Suppl. 1980;4:163–170
  22. Saibishkumar EP, Patel FD, Sharma SC, et al. Prognostic value of response to external radiation in Stage IIIB cancer cervix in predicting clinical outcomes: A retrospective analysis of 556 patients from India. Radiother Oncol. 2006;79:142–146
  23. Nijhuis ER, van der Zee AG, in 't Hout BA, et al. Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery. Int J Radiat Oncol Biol Phys. 2006;66:699–705
  24. Moyses HM, Morrow CP, Muderspach LI, et al. Residual disease in the uterus after preoperative radiotherapy and hysterectomy in Stage IB cervical carcinoma. Am J Clin Oncol. 1996;19:433–438
  25. Rouzier R, Morice P, De Crevoisier R, et al. Survival in cervix cancer patients treated with radiotherapy followed by radical surgery. Eur J Surg Oncol. 2005;31:424–433
  26. Oka K, Nakano T, Hoshi T. Analysis of response to radiation therapy of patients with cervical adenocarcinoma compared with squamous cell carcinoma. MIB-1 and PC10 labeling indices. Cancer. 1996;77:2280–2285
  27. Straughn JM, Oliver PG, Zhou T, et al. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol Oncol. 2006;101:46–54
  28. Greco FA, Bonomi P, Crawford J, et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non–small cell lung cancer. Lung Cancer. 2008;61:82–90
  29. Plummer R, Attard G, Pacey S, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res. 2007;13:6187–6194

 Supported by the Dutch Cancer Society by a personal grant to J. H. Maduro and Grants RUG 2000-2289 and 2005-3365.

 Conflict of interest: none.

PII: S0360-3016(09)00718-4

doi: 10.1016/j.ijrobp.2009.03.071

International Journal of Radiation Oncology * Biology * Physics
Volume 75, Issue 1 , Pages 203-211 , 1 September 2009

Article Tools

* Image Usage & Resolution